Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
British Columbia Cancer Agency |
---|---|
Information provided by: | British Columbia Cancer Agency |
ClinicalTrials.gov Identifier: | NCT00207298 |
Positron emission tomography (PET) is a nuclear medicine procedure based on the measurement of positron emission from radiolabelled tracer molecules. These radiotracers allow biologic processes to be measured and whole body images to be obtained which demonstrates sites of radiotracer accumulation. The most common radiotracer in use today is 18F-fluorodeoxyglucose (18F-FDG) which is a radiolabelled sugar (glucose) molecule. Imaging with 18F-FDG PET is used to determine sites of abnormal glucose metabolism and can be used to characterize and localize many types of tumours.
Cancer treatment and outcome depend largely on the accurate diagnosis and staging of disease. There is extensive data in the literature indicating the importance of FDG-PET imaging in accurately characterizing disease, as well as determining stage and sites of recurrent disease in many cancer types. For these indications, functional imaging with PET provides unique information which is not available from standard medical imaging modalities such as ultrasound, X-ray, computerized tomography (CT) or magnetic resonance imaging (MRI).
The objectives of this study are to document the safety and efficacy of 18F-FDG produced by the British Columbia Cancer Agency (BCCA) at its Tri-University Meson Facility (TRIUMF) production facility and to evaluate FDG-PET as a diagnostic and decision making tool in the management of oncology patients in British Columbia. With a population base of over 4 million people, standardized cancer treatment protocols, and evidence based guidelines for FDG-PET imaging, the BCCA is positioned to make an important contribution to defining the role of PET in the Canadian health care system.
Condition | Intervention | Phase |
---|---|---|
Brain Neoplasms Lung Neoplasms Lymphoma Melanoma Colorectal Neoplasms |
Procedure: Positron Emission Tomography |
Phase III |
Study Type: | Interventional |
Study Design: | Diagnostic, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase III Open Label Trial for Use of [18F]-Fluoro-Deoxy-Glucose (18F-FDG) in Positron Emission Tomography Imaging in Oncology |
Estimated Enrollment: | 5000 |
Study Start Date: | June 2005 |
Estimated Study Completion Date: | November 2008 |
Ages Eligible for Study: | 19 Years to 90 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Don C Wilson, MD | 604-707-5979 | dowilson@bccancer.bc.ca |
Canada, British Columbia | |
BCCA, Vancouver Centre | Recruiting |
Vancouver, British Columbia, Canada, V5Z 4E6 | |
Contact: Don C Wilson, MD 604-707-5979 dowilson@bccancer.bc.ca |
Principal Investigator: | Don C Wilson, MD | British Columbia Cancer Agency |
Study ID Numbers: | R05-0076 |
Study First Received: | September 13, 2005 |
Last Updated: | June 26, 2007 |
ClinicalTrials.gov Identifier: | NCT00207298 History of Changes |
Health Authority: | Canada: Health Canada |
Thoracic Neoplasms Gastrointestinal Diseases Colonic Diseases Central Nervous System Neoplasms Brain Diseases Rectal Diseases Melanoma Respiratory Tract Diseases Lung Neoplasms Nevus, Pigmented Neoplasms, Germ Cell and Embryonal Neuroepithelioma Lymphoma Nervous System Neoplasms Digestive System Neoplasms |
Immunoproliferative Disorders Central Nervous System Diseases Intestinal Diseases Intestinal Neoplasms Neuroendocrine Tumors Brain Neoplasms Lymphatic Diseases Neuroectodermal Tumors Digestive System Diseases Lung Diseases Deoxyglucose Gastrointestinal Neoplasms Nevus Lymphoproliferative Disorders Colorectal Neoplasms |
Thoracic Neoplasms Gastrointestinal Diseases Neoplasms, Nerve Tissue Colonic Diseases Central Nervous System Neoplasms Brain Diseases Rectal Diseases Melanoma Neoplasms by Site Respiratory Tract Diseases Lung Neoplasms Neoplasms, Germ Cell and Embryonal Nevi and Melanomas Lymphoma Nervous System Neoplasms |
Respiratory Tract Neoplasms Immunoproliferative Disorders Digestive System Neoplasms Neoplasms by Histologic Type Immune System Diseases Nervous System Diseases Central Nervous System Diseases Intestinal Diseases Intestinal Neoplasms Neuroendocrine Tumors Neuroectodermal Tumors Lymphatic Diseases Brain Neoplasms Neoplasms Digestive System Diseases |